Neurocrine Biosciences to Present at the 2026 Jefferies Global Healthcare ConferencePRNewsWire • Tuesday
Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid ChoiceZacks Investment Research • Monday
Wall Street Analysts See a 25.53% Upside in Neurocrine (NBIX): Can the Stock Really Move This High?Zacks Investment Research • Monday
Neurocrine Biosciences Presents New Tardive Dyskinesia Survey Results Showing Fewer Work and School Disruptions with INGREZZA® (valbenazine) CapsulesPRNewsWire • 11/05/26
Neurocrine Biosciences: Up 15% After Q3, And The Research Engine Is Still Almost FreeSeeking Alpha • 11/04/26
Neurocrine Biosciences to Spotlight Its Scientific Journey and Growing Neuropsychiatry Pipeline at 2026 NEI Fall CongressPRNewsWire • 11/03/26
NBIX Beats on Q3 Earnings & Sales, Raises '26 Ingrezza Sales ViewZacks Investment Research • 11/03/26
Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top EstimatesZacks Investment Research • 11/03/26
Neurocrine (NBIX) Reports Q3 Earnings: What Key Metrics Have to SayZacks Investment Research • 11/03/26
Here's Why Neurocrine Biosciences (NBIX) is a Strong Growth StockZacks Investment Research • 10/30/26
Neurocrine Biosciences Launches Interactive Educational Resources to Support Clinical Learning in Classic Congenital Adrenal HyperplasiaPRNewsWire • 10/30/26
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?Zacks Investment Research • 10/26/26
Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive DyskinesiaPRNewsWire • 10/26/26
Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi SyndromePRNewsWire • 10/22/26
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's DiseasePRNewsWire • 10/20/26